Anaya-Ruiz Maricruz, Bandala Cindy, Martinez-Morales Patricia, Landeta Gerardo, Martinez-Contreras Rebeca D, Martinez-Montiel Nancy, Perez-Santos Martin
Laboratorio de Biologia Celular, Centro de Investigacion Biomedica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Puebla CP 74360, Mexico.
Neurosciences Department, National Institute of Rehabilitation, Mexico City, Mexico.
Recent Pat Anticancer Drug Discov. 2018;13(3):348-359. doi: 10.2174/1574892813666180430113605.
Despite dramatic advances in cancer treatment that lead to long-term survival, there is an increasing number of patients presenting with clinical manifestations of cerebral metastasis in breast cancer, for whom only palliative treatment options exist.
The present review based on researches aims to provide identification of recent patens of breast cancer brain metastasis that may have application in improving cancer treatment.
Recent patents regarding the breast cancer brain metastasis were obtained from USPTO patent databases, Esp@cenet, Patentscope and Patent Inspiration®.
A total of 55 patent documents and 35 drug targets were recovered. Of these, a total of 45 patents and 10 patents were biotech drugs and chemical drugs, respectively. Among the target drugs analyzed were neurotrophin-3, protocadherin 7, CXCR4, PTEN, GABA receptor 3, L1CAM, PI3K-Akt / mTOR, VEGFR2, Claudin-5, Occludin, and NKG2A, among others.
In this study, we found 35 drug targets for metastasis to the brain in breast cancer, with 60% of them including only one patent, which establishes that this area of research is very recent, and that these targets have recently been linked to metastasis to the brain. On the other hand, 19 drug targets, among them VEGF, VEGFR2, CXCL12, and CXCR4, have been addressed for the first time until 6 years ago, confirming that the development of drugs for brain metastasis in breast cancer is an incipient area, but with interesting potential. Interestingly, the stage of inside the brain, was the stage with the lowest amount of drug targets, which places it as a priority for research and drug development.
尽管癌症治疗取得了显著进展，使患者能够长期存活，但越来越多的乳腺癌患者出现脑转移的临床表现，而针对这些患者只有姑息治疗方案。
本综述基于研究旨在识别乳腺癌脑转移的最新模式，这些模式可能有助于改善癌症治疗。
从美国专利商标局专利数据库、欧洲专利局专利数据库、世界知识产权组织专利数据库和专利灵感数据库获取有关乳腺癌脑转移的近期专利。
共检索到55篇专利文献和35个药物靶点。其中，分别有45项专利和10项专利涉及生物科技药物和化学药物。在所分析的靶点药物中，包括神经营养因子-3、原钙黏蛋白7、CXC趋化因子受体4、磷酸酶和张力蛋白同源物、γ-氨基丁酸受体3、神经细胞黏附分子L1、磷脂酰肌醇-3激酶-蛋白激酶B/哺乳动物雷帕霉素靶蛋白、血管内皮生长因子受体2、闭合蛋白5、紧密连接蛋白和自然杀伤细胞2A等。
在本研究中，我们发现了35个乳腺癌脑转移的药物靶点，其中60%的靶点仅有一项专利，这表明该研究领域非常新，且这些靶点最近才与脑转移相关联。另一方面，19个药物靶点，包括血管内皮生长因子、血管内皮生长因子受体2、CXC趋化因子配体12和CXC趋化因子受体4等，直到6年前才首次被提及，这证实了乳腺癌脑转移药物的开发是一个新兴领域，但具有有趣的潜力。有趣的是，脑内阶段是药物靶点数量最少的阶段，这使其成为研究和药物开发的重点。
Zotero 插件